Cargando…

E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma

Detalles Bibliográficos
Autores principales:	Maksimos, Mina, Muz, Barbara, Magnani, John L., Azab, Abdel Kareem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081993/ https://www.ncbi.nlm.nih.gov/pubmed/37029121 http://dx.doi.org/10.1038/s41408-023-00828-4

Ejemplares similares

Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy
por: Muz, Barbara, et al.
Publicado: (2019)

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib
por: Muz, Barbara, et al.
Publicado: (2015)

Tumor-associated macrophages in multiple myeloma: advances in biology and therapy
por: Sun, Jennifer, et al.
Publicado: (2022)

Targeting E-selectin to Tackle Cancer Using Uproleselan
por: Muz, Barbara, et al.
Publicado: (2021)

Molecularly Targeted Therapies in Multiple Myeloma
por: de la Puente, Pilar, et al.
Publicado: (2014)

Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma
por: Federico, Cinzia, et al.
Publicado: (2020)

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
por: Muz, Barbara, et al.
Publicado: (2017)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
por: Muz, Barbara, et al.
Publicado: (2016)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Andersen, Kristian T., et al.
Publicado: (2020)

CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies
por: Sun, Jennifer, et al.
Publicado: (2021)

Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells
por: Muguruma, Yukari, et al.
Publicado: (2017)

The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
por: Muz, Barbara, et al.
Publicado: (2015)

Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians
por: Banerjee, Rahul, et al.
Publicado: (2023)

Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
por: Mohty, Mohamad, et al.
Publicado: (2020)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
por: Nooka, Ajay K., et al.
Publicado: (2022)

Bortezomib Reduces the Tumorigenicity of Multiple Myeloma via Downregulation of Upregulated Targets in Clonogenic Side Population Cells
por: Nara, Miho, et al.
Publicado: (2013)

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study
por: Mina, Roberto, et al.
Publicado: (2020)

A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma
por: Alhallak, Kinan, et al.
Publicado: (2021)

Hypoxia promotes stem cell-like phenotype in multiple myeloma cells
por: Muz, B, et al.
Publicado: (2014)

Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
por: Sun, Jennifer, et al.
Publicado: (2020)

MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma
por: de la Puente, P, et al.
Publicado: (2016)

Plasma P‐selectin is an early marker of thromboembolism in COVID‐19
por: Fenyves, Bánk G., et al.
Publicado: (2021)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial
por: Ramasamy, Karthik, et al.
Publicado: (2022)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271
por: Natoni, A, et al.
Publicado: (2017)

Nanoparticle T cell engagers for the treatment of acute myeloid leukemia
por: Alhallak, Kinan, et al.
Publicado: (2021)

Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1
por: Zhou, Xiang, et al.
Publicado: (2023)

Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy
por: Alhallak, Kinan, et al.
Publicado: (2021)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Biological Insights into Myeloma and Other B Cell Malignancies
por: Fulciniti, Mariateresa, et al.
Publicado: (2016)

Clinical outcomes of bortezomib-based therapy in myeloma
por: Djebbari, Faouzi, et al.
Publicado: (2018)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
por: Kaloyannidis, Panayotis, et al.
Publicado: (2018)

Magnesium sulphate intravenously reduces tachycardia side-effects of β(2)-agonists
por: Sellers, William F.S., et al.
Publicado: (2022)

Bortezomib: the evidence of its clinical impact in multiple myeloma
por: Lancaster, Simon
Publicado: (2006)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Tumor lysis syndrome in multiple myeloma treated with bortezomib
por: Dhanraj, K. M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_sfna95nuqvue6p9o1cms117ho3